The site will be unavailable from 11:00 PM GMT on Tuesday, 21 July 2026, until 4:00 AM GMT on Wednesday, 22 July 2026, due to scheduled maintenance.

This is a plain language summary of a clinical research study. The studyinvestigated the effects of a drug called anamorelin for people in Japan withadvanced gastrointestinal cancer (colon, rectum, stomach or pancreas) whoalso had a condition called cachexia.People with cachexia have a loss of appetite, severe weight loss, loss of bodyfat, and loss of muscle. Anamorelin has been shown in previous researchstudies to improve appetite and increase lean body mass (the total weight of the body, not counting fat) and overall bodyweight. In this study, participants were given anamorelin (100 mg daily) for 12 weeks.This Plain Language Summary of Publication article (PLSP) from Future Oncology summarises the results of a study that looked at the effectiveness of a drug called anamorelin to treat Japanese people with advanced gastrointestinal cancer (colon, rectum, stomach or pancreas) who also had a condition called cachexia. People with cachexia have a loss of appetite, severe weight loss, and loss of body fat and muscle.

Visit the site using the link to read the article.

This PLSP is based on an article called ‘A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia’ that was published in Cancer.

Visit the American Cancer Society Journals site using the link to read the article.